Hepion Pharmaceuticals (HEPA) director Stetz submits initial insider Form 3

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director Gary S. Stetz II filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and, based on the structured data, reports no insider purchase, sale, exercise, gift, or other transaction activity.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative transactions: 0 +1 more

4 metrics

Buy transactions 0 buyCount in the transaction summary for this Form 3

Sell transactions 0 sellCount in the transaction summary for this Form 3

Derivative transactions 0 derivativeTransactionCount in the transaction summary

Net shares bought or sold 0 netBuySellShares reported as neutral activity

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/10/2026 - 07:50 PM Accepted by SEC EDGAR 07/10/2026 - 07:49 PM Learn about SEC filing dates

FAQ

What does the HEPA Form 3 filed by Gary S. Stetz II represent?

The HEPA Form 3 for Gary S. Stetz II is an initial statement of beneficial ownership as he serves as a director of Hepion Pharmaceuticals, Inc. It establishes his insider status with the SEC.

Is Gary S. Stetz II a director or officer of Hepion Pharmaceuticals (HEPA)?

In this Form 3, Gary S. Stetz II is identified as a director of Hepion Pharmaceuticals, Inc. He is not reported as an officer or ten percent owner in the structured data.

Does the HEPA Form 3 for Gary S. Stetz II show any insider trades?

The structured data for this HEPA Form 3 shows no reported transactions, with zero purchases, sales, exercises, gifts, tax withholdings, or restructuring entries for Gary S. Stetz II.

What is the net share activity reported in the HEPA Form 3?

For this HEPA Form 3, the transaction summary indicates netBuySellShares of 0 and a net buy/sell direction of neutral, reflecting no reported insider transaction activity.

Does the HEPA Form 3 include derivative transactions for Gary S. Stetz II?

According to the structured data, the HEPA Form 3 lists derivativeTransactionCount as 0 and an empty derivative summary, indicating no reported option or other derivative activity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stetz Gary S. II

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Gary S. Stetz, II	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)